Biodyne Co., Ltd.
Financials
Valuation Metrics
Biodyne Co., Ltd.'s Market Cap is ₩1997B. At end of 2025 it was ₩4018B. Ranked #855 of 2,421 in KR market (top 35%), #400 of 1,640 on KOSDAQ (top 24%), #26 of 96 in Health Care Equipment & Services (top 27%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 199.72B KRW | KR#855/2,421 Sec#26/96 |
| Revenue | 5.77B KRW | KR#2,329/2,421 Sec#86/96 |
| Net Income | 1.22B KRW | KR#1,464/2,421 Sec#46/96 |
| Total Assets | 44.94B KRW | KR#2,248/2,421 Sec#79/96 |
| Net Assets | 44.07B KRW | KR#1,990/2,421 Sec#66/96 |
| Employees | 19 | KR#2,255/2,421 Sec#91/96 |
| Value | ||
| P/E | 163.33x | KR#1,516/2,421 Sec#48/96 |
| P/B | 4.53x | KR#2,219/2,421 Sec#87/96 |
| P/S | 34.59x | KR#2,363/2,421 Sec#93/96 |
| EV/EBITDA | 2420.92x | KR#1,570/2,421 Sec#51/96 |
| FCF Yield | -1.30% | KR—/2,421 Sec—/96 |
| Profitability | ||
| ROE | 2.77% | KR#1,341/2,421 Sec#47/96 |
| ROA | 2.72% | KR#1,088/2,421 Sec#42/96 |
| Op. Margin | 1.34% | KR#1,466/2,421 Sec#49/96 |
| Revenue Growth | 2.36% | KR#1,360/2,421 Sec#69/96 |
| Financial Health | ||
| Debt Ratio | 1.98% | KR#8/2,421 Sec#1/96 |
| Total Debt | 0 KRW | KR—/2,421 Sec—/96 |
| FCF | -2.60B KRW | KR#1,372/2,421 Sec#45/96 |
| Cash | 12.98B KRW | KR#1,537/2,421 Sec#46/96 |
| Current Ratio | 45.95x | KR#6/2,421 Sec#1/96 |
| Performance | ||
| 1Y Return | -52.24% | KR#2,090/2,421 Sec#73/96 |
| 1M Return | -9.93% | KR#2,096/2,421 Sec#77/96 |
| From 52W High | -60.20% | KR#1,868/2,421 Sec#63/96 |
| 1Y MDD | -59.47% | KR#1,448/2,421 Sec#49/96 |
| Trading | ||
| Volume | 16,888 shares | KR#1,660/2,421 Sec#62/96 |
| Trading Value | 113.3M KRW | KR#1,494/2,421 Sec#62/96 |
| Foreign Own. | 4.32% | KR#977/2,421 Sec#32/96 |
| Per Share | ||
| EPS | 41 KRW | KR#1,510/2,421 Sec#48/96 |
| BPS | 1,481 KRW | KR#2,200/2,421 Sec#80/96 |
Company Info
Established in 2013, the company develops, manufactures, and sells liquid-based cytology equipment and cancer diagnostic reagent kits, completing a special listing on the KOSDAQ market in 2021. It exports its independently developed blowing technology-based LBC equipment, 'PATHPLORER', and reagent kits to 13 countries, securing patents in multiple nations. The company has an exclusive license agreement with Roche for slide smearing device development, planning to unveil 'VENTANA SP400' in Japan in 2025 and pursue global sales. Biodine is headquartered in Seongdong-gu, Seoul.